Last updated: March 2026
The two primary female sex hormones used in hormone replacement therapy. Estradiol (0.5-2mg) and progesterone (100-200mg) — what the research shows about benefits, risks, and the controversial WHI study that changed everything in 2002.
These two hormones work together in the female reproductive system. Estradiol (the strongest estrogen) is produced by the ovaries and declines sharply at menopause. Progesterone prepares the uterine lining for pregnancy and balances estrogen's effects.
Estradiol (E2) is the most potent form of estrogen. It maintains vaginal health, supports bone density, regulates mood, and affects cardiovascular health. Levels drop 80-90% at menopause, causing most menopausal symptoms. Transdermal estradiol may have better cardiovascular profile than oral.
Progesterone balances estradiol's effects on the endometrium. Without progesterone, unopposed estrogen increases endometrial cancer risk. Micronized progesterone (like Prometrium) is considered safer than synthetic progestins for the endometrium and may have better side effect profile.
The 'timing hypothesis' suggests HRT started within 10 years of menopause onset has different (more favorable) risk-benefit profile than starting later. The window of opportunity for cardiovascular benefits appears to be ages 50-59 or within 10 years of menopause onset.
Bioidentical = chemically identical to human hormones. Synthetic = similar but different structure. The 'bioidentical' label is marketing, not a scientific claim. Compounded HRT is NOT proven safer than pharmaceutical HRT and carries the same risks. FDA-approved bioidentical options exist (e.g., Vivelle-Dot, Climara).
The WHI was a landmark study that enrolled over 27,000 postmenopausal women. Initial results in 2002 dramatically changed HRT prescribing patterns. Later reanalysis refined our understanding.
Healthy women under 60 within 10 years of menopause onset with moderate-to-severe vasomotor symptoms (hot flashes, night sweats). Women with premature ovarian insufficiency (before age 40) typically benefit more than they risk. Those with genitourinary syndrome of menopause (vaginal dryness, dyspareunia).
Women with history of breast cancer, coronary heart disease, previous VTE or stroke, active liver disease, or unexplained vaginal bleeding. Those starting HRT more than 10 years after menopause onset may have increased cardiovascular risk.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational purposes only. It is not medical advice. HRT involves significant individual risks and benefits that must be evaluated by a qualified healthcare provider. The WHI study showed both benefits and risks. Compounded bioidentical hormones are NOT proven safer than FDA-approved options. Always consult a physician before starting or stopping HRT.